[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR20010031149A - 항소양 활성을 가진 화합물의 신규한 용도 - Google Patents

항소양 활성을 가진 화합물의 신규한 용도 Download PDF

Info

Publication number
KR20010031149A
KR20010031149A KR1020007004053A KR20007004053A KR20010031149A KR 20010031149 A KR20010031149 A KR 20010031149A KR 1020007004053 A KR1020007004053 A KR 1020007004053A KR 20007004053 A KR20007004053 A KR 20007004053A KR 20010031149 A KR20010031149 A KR 20010031149A
Authority
KR
South Korea
Prior art keywords
xanthine
compound
cyclopropylmethyl
nitro
butyl
Prior art date
Application number
KR1020007004053A
Other languages
English (en)
Korean (ko)
Inventor
돈 이. 그리스월드
지그프리드 벤자민4세 크리스텐슨
Original Assignee
스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스
스미스클라인 비참 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스, 스미스클라인 비참 코포레이션 filed Critical 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스
Publication of KR20010031149A publication Critical patent/KR20010031149A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020007004053A 1997-10-17 1998-10-16 항소양 활성을 가진 화합물의 신규한 용도 KR20010031149A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6374697P 1997-10-17 1997-10-17
US60/063,746 1997-10-17
PCT/US1998/021886 WO1999020280A1 (en) 1997-10-17 1998-10-16 Novel use of compounds for anti-pruritic activity

Publications (1)

Publication Number Publication Date
KR20010031149A true KR20010031149A (ko) 2001-04-16

Family

ID=22051225

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007004053A KR20010031149A (ko) 1997-10-17 1998-10-16 항소양 활성을 가진 화합물의 신규한 용도

Country Status (18)

Country Link
EP (1) EP1030666A4 (xx)
JP (1) JP2001520196A (xx)
KR (1) KR20010031149A (xx)
CN (1) CN1306426A (xx)
AR (1) AR015966A1 (xx)
AU (1) AU740875B2 (xx)
BR (1) BR9814080A (xx)
CA (1) CA2306985A1 (xx)
CO (1) CO4810374A1 (xx)
CZ (1) CZ20001376A3 (xx)
HU (1) HUP0003792A3 (xx)
IL (1) IL135581A0 (xx)
NO (1) NO20001847D0 (xx)
NZ (1) NZ503551A (xx)
PL (1) PL341062A1 (xx)
TR (1) TR200001040T2 (xx)
WO (1) WO1999020280A1 (xx)
ZA (1) ZA989450B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116850A (pt) 2001-01-31 2004-02-25 Pfizer Prod Inc Derivados de amida de ácido tiazolil-, oxazolil-, pirrolil- e imidazolil- úteis como inibidores de isoenzimas de pde4
ATE305467T1 (de) 2001-01-31 2005-10-15 Pfizer Prod Inc Als inhibitoren von pde4-isozymen geeignete etherderivate
SK8792003A3 (en) 2001-01-31 2004-09-08 Pfizer Prod Inc Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes and pharmaceutical composition containing them
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
US20030175314A1 (en) * 2001-11-19 2003-09-18 Didriksen Erik Johannes Pharmaceutical composition for dermal application
US20060258703A1 (en) * 2003-07-17 2006-11-16 Ono Pharmaceutical Co., Ltd. Remedy for pruritus comprising piperidine derivative as the active ingredient
JP2005187458A (ja) * 2003-12-04 2005-07-14 Santen Pharmaceut Co Ltd シロミラストまたはその塩を有効成分とする掻痒治療剤
WO2005053672A1 (ja) * 2003-12-04 2005-06-16 Santen Pharmaceutical Co., Ltd. シロミラストまたはその塩を有効成分とする掻痒治療剤
AU2005212816C1 (en) * 2004-02-14 2010-03-04 Glaxosmithkline Llc Novel compounds
JP2008137892A (ja) * 2005-03-04 2008-06-19 Eisai Co Ltd 止痒剤
TW200800217A (en) 2005-08-10 2008-01-01 Smithkline Beecham Corp Novel compounds
TWI404709B (zh) * 2006-02-21 2013-08-11 Eisai R&D Man Co Ltd 4- (3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives
WO2007097317A1 (ja) * 2006-02-21 2007-08-30 Eisai R & D Management Co., Ltd. ４－（３－ベンゾイルアミノフェニル）－６，７－ジメトキシ－２－メチルアミノキナゾリン誘導体
AU2008215411B2 (en) 2007-02-16 2012-11-22 Eisai R & D Management Co., Ltd. Crystal, amorphous form and salt of methyl N-[3-(6,7-dimethoxy- 2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid
CN101687820B (zh) 2007-08-17 2012-07-25 卫材R&D管理有限公司 喹唑啉衍生物的制造方法
WO2009025239A1 (ja) 2007-08-17 2009-02-26 Eisai R & D Management Co., Ltd. 新規外用剤
ES2659458T3 (es) * 2011-06-28 2018-03-15 Mitsubishi Tanabe Pharma Corporation Compuestos de naftaleno para tratar el prurito
AU2016212625B2 (en) 2015-01-30 2020-03-26 Shanton Pharma Pte. Ltd. Prevention or treatment of uric acid or gout disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011260A1 (en) * 1990-12-21 1992-07-09 Beecham Group Plc Xanthine derivatives
EP0889886B1 (de) * 1996-03-26 2002-09-18 ALTANA Pharma AG Neue in 6-position substituierte phenanthridine
ES2187775T3 (es) * 1996-05-15 2003-06-16 Altana Pharma Ag Imidazopiridinas.
WO1998040382A1 (en) * 1997-03-07 1998-09-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel tetrazoles
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
SI0988302T1 (en) * 1997-06-03 2003-08-31 Altana Pharma Ag Benzonaphthyridines

Also Published As

Publication number Publication date
HUP0003792A3 (en) 2001-12-28
CZ20001376A3 (cs) 2002-06-12
NO20001847L (no) 2000-04-10
AU1093899A (en) 1999-05-10
HUP0003792A2 (hu) 2001-10-28
TR200001040T2 (tr) 2001-01-22
CN1306426A (zh) 2001-08-01
AR015966A1 (es) 2001-05-30
IL135581A0 (en) 2001-05-20
NZ503551A (en) 2002-05-31
EP1030666A1 (en) 2000-08-30
ZA989450B (en) 1999-04-19
PL341062A1 (en) 2001-03-26
CO4810374A1 (es) 1999-06-30
AU740875B2 (en) 2001-11-15
EP1030666A4 (en) 2002-10-16
CA2306985A1 (en) 1999-04-29
BR9814080A (pt) 2000-09-26
JP2001520196A (ja) 2001-10-30
NO20001847D0 (no) 2000-04-10
WO1999020280A1 (en) 1999-04-29

Similar Documents

Publication Publication Date Title
KR20010031149A (ko) 항소양 활성을 가진 화합물의 신규한 용도
JP2002527392A (ja) 末梢的に作用する抗掻痒アヘン剤
KR20010021865A (ko) 카파 작용제 항소양성 약학적 조성물 및 이를 이용한소양증의 치료 방법
JP5535088B2 (ja) いぼ、肬贅および乾癬性プラークの治療のための、サンギナリン、ケレリトリンまたはケリドニンを有する製剤
AU2016244263A1 (en) Combination ALS therapy
KR20010021854A (ko) 말초 작용성 항소양성 아편제
US20110118317A1 (en) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
KR930009786B1 (ko) 특정 paf 길항제/항히스타민제 조성물
JPH039089B2 (xx)
CA1094454A (en) Treatment for scabies
NL8002041A (nl) Werkwijze voor het bereiden van een analgetisch en myotonolytisch geneesmiddel.
JPH03215435A (ja) アルドース還元酵素阻害剤を主成分とする潰瘍治療剤
MXPA00003775A (en) Novel use of compounds for anti-pruritic activity
CA2083611A1 (en) Use of platelet activating factor antagonists as anti-pruritic agents
Flowers et al. Antihistamines.
US6090829A (en) Method for treating excessive aggression
JPH10500427A (ja) アレルギー性結膜炎を治療するための２−（４−（アゾリルブチル）−ピペラジニル−メチル）−ベンズイミダゾール誘導体の使用
AU5010193A (en) Methods of treating psoriasis employing substituted azaspiranes
JPH04210631A (ja) 消化管壁保護剤
JPH0653678B2 (ja) アレルギ−性疾患治療剤
Murphy Antihistamine toxicosis
JPH06172220A (ja) 虚血性疾患治療用医薬組成物
US20070208080A1 (en) A composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases
Turner Benoxinate. See OXYBUPROCAINE.
AU1563902A (en) Novel use of compounds for anti-pruritic activity

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid